B Vitamins and Homocysteine

Homocysteine moved. The disease did not.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you have read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not to replace medical care.

In brief: Elevated homocysteine reliably predicts heart attacks and strokes in observational studies, and the proposed mechanisms — endothelial damage, oxidative stress, accelerated atherosclerosis — are detailed and biologically plausible. (6) B vitamins (folate, B6, B12) lower homocysteine by roughly 20–28% in every trial that has tested them. (1,2,3,4,5) But across more than 30,000 patients in five large randomized trials over two decades, lowering homocysteine with B vitamins did not reduce cardiovascular events, and one trial recorded a harm signal in post-MI patients on a combined high-dose formulation. (1,2,3,4,5,7) The most consistent explanation is that elevated homocysteine marks underlying metabolic dysfunction — kidney impairment, inflammation, vascular disease itself — rather than driving cardiovascular risk. B vitamins retain established roles in neural-tube-defect prevention and in treating documented deficiency; cardiovascular event prevention is not among them.

Introduction

For two decades, homocysteine looked like the clearest causal target in cardiovascular prevention.

The observational data were unusually strong. In a meta-analysis combining 20 prospective cohort studies, every 5 μmol/L rise in homocysteine was associated with roughly 30% higher risk of coronary disease and 60% higher risk of stroke, and 72 genetic studies of a homocysteine-raising gene variant pointed the same way. (6) The biology made mechanical sense: homocysteine damaged endothelial cells in lab studies, oxidized LDL, impaired nitric oxide signaling, and promoted clotting. The genetic evidence seemed to clinch it — patients with homocystinuria, a rare disorder producing extreme elevations, developed severe premature atherosclerosis, sometimes fatal in early adulthood.

The intervention was almost too convenient. B vitamins — folate, B6, B12 — are the cofactors the body uses to clear homocysteine. Supplementing them lowered homocysteine reliably, by 20–28%, in every trial that tested them. (1,2,3,4,5) Inexpensive, safe, biologically targeted, mechanistically coherent. If lowering homocysteine reduced cardiovascular risk, this was how it would be done.

The trials produced a different answer.

HOPE-2, NORVIT, VISP, SEARCH, and VITATOPS — five large randomized trials enrolling more than 30,000 patients between 2004 and 2010 — lowered homocysteine as expected, by roughly a quarter, every time. (1,2,3,4,5) The Clarke 2010 meta-analysis then pooled eight trials and 37,485 individuals followed for an average of five years. (7) No reduction in cardiovascular events. No reduction in coronary disease. No reduction in stroke. No reduction in all-cause mortality.

Homocysteine is a different kind of marker failure than vitamin D (Article 15). Vitamin D’s level reflected underlying ill health — illness lowered the level, and the level was a downstream signal that intervention could not meaningfully reverse for cardiovascular ends. Homocysteine can be moved by intervention. The trials moved it. Moving it did not change what happened to the patient.

Where the Evidence Stands

For B vitamins and cardiovascular prevention, the evidence has been tested at the level that matters most — randomized trials measuring cardiovascular events directly — and the result is negative. Multiple large trials in more than 30,000 patients found no benefit; one trial (NORVIT) recorded a harm signal in post-MI patients on a combined high-dose formulation. For neural-tube-defect prevention and for correcting documented deficiency, the evidence is established and favorable. This describes what the trials found; it is information to inform a conversation with a clinician, not a basis for starting or stopping a supplement independently.

Find Your Situation

The table identifies what the evidence supports for specific clinical profiles. Each entry is examined in the sections that follow.

The Hypothesis

Homocysteine is an amino acid produced during normal methionine metabolism. Elevated blood levels correlate strongly with cardiovascular disease — heart attacks, strokes, peripheral arterial disease, and venous thrombosis. (6) The association appears across populations and persists after adjustment for traditional risk factors.

The biological mechanisms were compelling. Homocysteine damages endothelial cells (the inner lining of blood vessels), promotes oxidative stress, impairs nitric oxide signaling, increases platelet aggregation, and accelerates atherosclerosis in animal models.

The solution seemed obvious. B vitamins — folate, B6, and B12 — are the cofactors that metabolize homocysteine. Supplementing them reliably lowers homocysteine levels by 20–28%. (1,2,3,4,5) If elevated homocysteine causes cardiovascular disease, and B vitamins lower homocysteine, then B vitamin supplementation should prevent heart attacks and strokes.

The logic was internally consistent. It failed externally.

Homocysteine Metabolism: Why B Vitamins Lower the Marker

The biochemistry is unambiguous and not disputed. Methionine — an essential amino acid from dietary protein — is converted to S-adenosylmethionine (SAM), the body’s primary methyl donor. After SAM donates its methyl group, it becomes homocysteine. The body clears homocysteine through two main pathways.

Remethylation converts homocysteine back to methionine, using folate (as 5-methyltetrahydrofolate) and vitamin B12 as essential cofactors. Transsulfuration converts homocysteine to cysteine, using vitamin B6 as a cofactor.

When folate, B12, or B6 are insufficient, these clearance pathways slow and homocysteine accumulates. Providing supraphysiological amounts of these cofactors accelerates clearance. Folate has the largest effect on homocysteine levels; B12 and B6 contribute additional lowering.

Clearing a metabolic intermediate faster does not necessarily address the underlying processes that elevate it in the first place.

The Observational Evidence: Why It Looked So Strong

Decades of observational research built an apparently ironclad case.

The Wald 2002 meta-analysis combined 20 prospective cohort studies and 72 genetic studies of the MTHFR gene variant. (6) For every 5 μmol/L increase in serum homocysteine, the odds ratio for ischemic heart disease was 1.32 (95% CI 1.19–1.45) and for stroke was 1.59 (95% CI 1.29–1.96) in the prospective studies. The genetic studies yielded similar effect estimates, which the authors interpreted as evidence the association was likely causal. Multiple other prospective cohorts showed elevated homocysteine independently predicting cardiovascular events after adjustment for traditional risk factors.

Genetic evidence seemed to clinch the case. Homocystinuria — a rare disorder causing severely elevated homocysteine, often above 100 μmol/L — causes severe premature atherosclerosis, with patients sometimes dying from cardiovascular disease in early adulthood. This appeared to prove that homocysteine itself was arterially toxic.

The biological plausibility was detailed. Lab studies showed endothelial damage, LDL oxidation, platelet aggregation, and impaired nitric oxide signaling at elevated homocysteine concentrations. The dose-response relationships were consistent. The intervention was safe and inexpensive.

The genetic argument deserves a closer look. Homocystinuria elevates homocysteine to levels five to ten times higher than the moderate elevations studied in cardiovascular trials. Whether a molecule that causes harm at extreme concentrations — as virtually every biological compound does — is causally relevant at modest elevations is a different question. The genetic disorder does not establish that the mild elevations (15–20 μmol/L) commonly seen in the general population are causally driving cardiovascular disease.

That distinction matters because the genetic argument was the primary basis for treating observational associations as causation. The argument was weaker than it appeared.

The Trial Evidence: What Actually Happened

Five large randomized trials tested the hypothesis directly across more than 30,000 patients, with the Clarke meta-analysis later pooling eight trials and 37,485 individuals.

HOPE-2 (2006). 5,522 patients with vascular disease or diabetes randomized to combined B vitamins (folic acid 2.5 mg, B6 50 mg, B12 1 mg daily) or placebo for five years. Homocysteine fell by approximately 20% in the treatment group. The primary cardiovascular composite — cardiovascular death, MI, or stroke — occurred at a hazard ratio of 0.95 (95% CI 0.84–1.07), not significant. (1) Among the secondary endpoints, the active group had fewer strokes (relative risk 0.75, 95% CI 0.59–0.97) but more hospitalizations for unstable angina (relative risk 1.24, 95% CI 1.04–1.49) — two significant findings pointing in opposite directions, neither the prespecified primary endpoint. Secondary results that scatter in both directions in an otherwise null trial are the reason such findings require independent confirmation; the stroke signal was not reproduced in the stroke-specific trials.

NORVIT (2006). 3,749 patients within 7 days of acute myocardial infarction randomized in a 2×2 factorial design to one of four arms: folic acid + B12 + B6; folic acid + B12; B6 alone; or placebo. Mean follow-up 3.5 years. Homocysteine fell by 28% in the folic acid groups. (2) The folic acid + B12 arm showed no benefit. The B6-alone arm showed no benefit. The combined three-vitamin arm showed a trend toward increased events (relative risk 1.22, 95% CI 1.00–1.50, P=0.05) — a signal substantial enough that the authors concluded such treatment “should not be recommended” in the post-MI population.

VISP (2004). 3,680 patients with prior nondisabling cerebral infarction randomized to high-dose B vitamins (folic acid 2.5 mg, B12 0.4 mg, B6 25 mg) or low-dose B vitamins for two years. (3) Risk ratio for any stroke, coronary event, or death: 1.0. No difference between groups, despite a measurable difference in homocysteine reduction.

SEARCH (2010). 12,064 patients with prior MI randomized — in the homocysteine arm of a 2×2 factorial trial — to folic acid 2 mg plus B12 1 mg daily or placebo, for a mean of 6.7 years, the longest and largest of the homocysteine trials. Homocysteine fell by 28%. The primary outcome of major vascular events occurred in 25.5% of the vitamin group versus 24.8% on placebo — a risk ratio of 1.04, essentially identical. (4)

VITATOPS (2010). 8,164 patients with recent stroke or TIA randomized to B vitamins (folic acid 2 mg, B6 25 mg, B12 0.5 mg) or placebo for a median of 3.4 years. No significant reduction in stroke, MI, or vascular death. (5)

Clarke meta-analysis (2010). Pooled 8 large trials including 37,485 individuals followed for an average of five years. (7) Homocysteine reduction with B vitamins did not reduce major cardiovascular events, coronary events, stroke, or all-cause mortality.

The Evidence at a Glance

The trial portfolio is unambiguous. Across study designs, populations, and B vitamin combinations producing consistent homocysteine reductions of 20–28%, no major cardiovascular outcome was reduced.

Why the Hypothesis Failed

The most consistent explanation is that elevated homocysteine reflects underlying metabolic dysfunction rather than driving cardiovascular risk. Kidney disease raises homocysteine and independently causes cardiovascular disease. Inflammation raises homocysteine. Cardiovascular disease itself impairs homocysteine metabolism. Multiple B vitamin combinations producing different degrees of homocysteine lowering all fail to reduce events. (1,2,3,4,5,7)

The stroke signal in HOPE-2. A secondary analysis showed a significant stroke reduction (RR 0.75), cited since as evidence that B vitamins have a selective stroke benefit. (1) It was a secondary endpoint in a trial whose primary endpoint was negative, and the same secondary analyses showed a significant increase in hospitalization for unstable angina (RR 1.24) — a signal in the opposite direction that receives far less attention. Neither VISP nor VITATOPS reproduced the stroke benefit. (3,5)

The harm signal in NORVIT. The combined three-vitamin arm showed a trend toward increased cardiovascular events (relative risk 1.22, P=0.05). (2) This was not a main effect — it appeared in one of four arms in a factorial trial — but the authors concluded the combination should not be recommended for post-MI secondary prevention.

The hypothesis was not poorly constructed. The observational evidence was as strong as any in cardiovascular epidemiology. (6) The biological mechanisms were detailed and real. The intervention was safe and biochemically effective. None of it translated.

MTHFR Variants and Cardiovascular Risk

The most common reason patients now ask about B vitamins is a genetic test result. Direct-to-consumer reports routinely flag the MTHFR C677T variant, which is common — roughly 10–15% of people carry two copies and 30–40% carry one in some populations. The C677T polymorphism reduces the activity of the MTHFR enzyme and modestly raises homocysteine. That biochemical fact has been marketed heavily as a reason to supplement: the argument is that carriers have impaired folate metabolism and therefore need extra B vitamins for cardiovascular protection.

The trial evidence does not support that argument. The major randomized trials lowered homocysteine effectively in their participants, and subgroup analyses by MTHFR genotype have not shown a consistent cardiovascular benefit in carriers. (7) A variant that modestly raises a marker, in a setting where lowering that marker did not change outcomes, does not become a cardiovascular indication. On current evidence, MTHFR variant status is not a basis for B vitamin supplementation specifically for cardiovascular prevention. Folate’s established value — neural tube defect prevention and the treatment of documented deficiency — applies to carriers and non-carriers alike, and any decision about supplementation is best made with a clinician who can weigh the individual’s full picture rather than a single genotype.

B Vitamins and Cardiovascular Guidelines

For some uses, B vitamins carry guideline-level support. For cardiovascular prevention, they do not.

Folate for neural tube defect prevention. The U.S. Preventive Services Task Force gives a Grade A recommendation for 400–800 mcg of folic acid daily for women planning or capable of pregnancy, and the U.S. Public Health Service has recommended folic acid for this purpose since 1992. (8) This is one of the strongest preventive recommendations in medicine, with decades of outcome data showing dramatic reductions in spina bifida and anencephaly.

Vitamin B12 for documented deficiency. Standard treatment for deficiency, pernicious anemia, and malabsorption conditions, and increasingly recognized as appropriate for older adults and strict vegans, in whom deficiency is common.

Folate for documented deficiency or methotrexate use. Standard medical practice.

Cardiovascular event prevention. No major cardiovascular guideline recommends B vitamin supplementation for prevention of heart attacks, strokes, or cardiovascular mortality. The 2018 ACC/AHA cholesterol guideline, the 2017 ACC/AHA hypertension guideline, the 2022 AHA/ACC/HFSA heart failure guideline, and the U.S. Preventive Services Task Force decline to recommend B vitamins for cardiovascular prevention. The 2014 AHA/ASA stroke prevention guidelines note that B vitamin supplementation is not recommended for primary or secondary stroke prevention. The trial evidence directly informed these positions.

What B Vitamins Actually Do

The cardiovascular prevention failure should not obscure B vitamins’ established clinical roles.

Folate (B9) prevents neural tube defects. Guidelines recommend that women who are or may become pregnant take folate (400–800 mcg daily) before and during early pregnancy. This is not a supplement story with uncertain evidence — it is established prevention with a clear causal mechanism and decades of outcome data. The same supplement that failed for cardiovascular prevention works dramatically for a different indication. Supplements can work, when they address a true causal mechanism in a population where that mechanism is operating. Folate deficiency also causes megaloblastic anemia, and documented deficiency requires treatment.

Vitamin B12 (cobalamin) is essential for neurological function and hematopoiesis. Deficiency — increasingly common with age due to reduced gastric acid and intrinsic factor production, and essentially universal in strict vegans without supplementation — causes peripheral neuropathy, cognitive impairment, and in severe cases irreversible spinal cord damage (subacute combined degeneration). B12 supplementation or monitoring is appropriate for older adults, vegans, people with pernicious anemia, and anyone with malabsorption conditions or sustained metformin use, which can reduce B12 absorption.

Vitamin B6 (pyridoxine) deficiency is uncommon in developed countries outside of alcohol use disorder, certain medications (isoniazid, hydralazine), or specific genetic conditions. It does not require routine supplementation in most people. High-dose B6 supplementation — above 100 mg daily for prolonged periods — can paradoxically cause sensory neuropathy.

Two Patients, Same Supplement Aisle, Different Answers

Both profiles below are composites built from the populations studied in the trials this article reviews.

Patient A: A 32-year-old woman planning her first pregnancy. Her primary care physician recommends 400 mcg of folic acid daily, started at least one month before conception and continued through the first trimester.

This is one of the most evidence-based supplement recommendations in modern medicine. Folate prevents neural tube defects through a clear causal mechanism, in the population where that mechanism is operating, with outcome data so strong that the U.S. mandated folic acid fortification of grain products in 1998. (8) The cardiovascular trials are not the relevant evidence base. She is taking folate to prevent spina bifida and anencephaly in her future child, and the evidence on that question is unambiguous. The 400 mcg dose is what guidelines recommend; higher doses do not improve neural tube outcomes and can complicate B12 deficiency screening later in life. Her supplement is doing exactly what supplements at their best can do.

Patient B: A 52-year-old man with mildly elevated LDL, BMI 28, and no prior cardiovascular events. A direct-to-consumer genetic testing report showed he carries one copy of the MTHFR C677T variant. He started a high-dose B-complex (folic acid 5 mg, B6 100 mg, B12 1 mg daily) after reading that MTHFR carriers need extra B vitamins to prevent cardiovascular disease.

The MTHFR variant raises homocysteine modestly. The B-complex will lower it. Neither fact connects to cardiovascular outcomes. Subgroup analyses across HOPE-2, NORVIT, and the other major trials have not shown that B vitamin supplementation reduces cardiovascular events in MTHFR carriers. (7) The marketing has run ahead of the trial evidence. There are also specific concerns with his regimen: folic acid 5 mg is well above the dose any indication requires and can mask a developing B12 deficiency on standard testing, and B6 100 mg sustained over years risks sensory neuropathy. The cardiovascular interventions that would reduce his risk — addressing his LDL, weight, and any blood pressure or glucose issues — are what the supplement displaces. The defensible step is to discuss his actual cardiovascular risk profile with his physician, using tools that have demonstrated outcome benefit.

Common Misconceptions

“My homocysteine is high, so I’m at higher cardiovascular risk and need to lower it.” Elevated homocysteine does associate with cardiovascular risk in observational studies. (6) The trials that directly tested whether lowering homocysteine reduces cardiovascular events have been done — five major trials, more than 30,000 patients — and the answer is no. (1,2,3,4,5,7) The homocysteine elevation is largely informational about underlying metabolic state, not a number to chase down with supplements.

“I have an MTHFR variant, so I need B vitamins to prevent cardiovascular disease.” MTHFR variants modestly raise homocysteine. Genetic testing companies and supplement marketers have aggressively promoted this as a cardiovascular indication. Subgroup analyses by MTHFR genotype across the major trials have not shown consistent cardiovascular benefit in carriers. (7) MTHFR variant status is not, on current evidence, a basis for B vitamin supplementation specifically as cardiovascular prevention.

“The HOPE-2 stroke finding means B vitamins prevent strokes.” HOPE-2 found a significant stroke reduction (RR 0.75) in a secondary analysis of a trial whose primary endpoint was negative — and, in the same secondary analyses, a significant increase in hospitalization for unstable angina (RR 1.24). (1) Taking the favorable secondary endpoint as proof while ignoring the unfavorable one is exactly the error to avoid. Neither VISP nor VITATOPS reproduced the stroke benefit. (3,5) Secondary endpoint findings in negative trials require independent confirmation, and that confirmation has not occurred.

“B vitamins are harmless even if they don’t help.” Mostly true at typical doses, but not universally. The NORVIT trial found a trend toward increased events in the combined three-vitamin arm post-MI. (2) High-dose B6 sustained over time can cause sensory neuropathy. High-dose folic acid can mask B12 deficiency. Combined high-dose B-vitamin products in post-MI patients are explicitly cautioned against in NORVIT.

“Folate prevents heart disease.” Folate prevents neural tube defects in pregnancy — that benefit is real, established, and one of the most important preventive interventions in medicine. Folate does not prevent heart attacks or strokes in adults. (1,2,3,4,5,7) The same supplement, two different indications, two different evidence bases.

“If observational studies are consistent and the biology is plausible, the supplement should work.” Here the observational evidence was as strong as any in cardiovascular epidemiology, the biological mechanisms were detailed and real, and the intervention was safe and biochemically effective. None of it translated. (1,2,3,4,5,7)

The Bottom Line

The homocysteine hypothesis was as well-constructed as any in cardiovascular prevention. The observational associations were consistent and large. (6) The biological mechanisms were detailed and plausible. The intervention was safe, inexpensive, and effective at its stated biochemical purpose. Across populations, study designs, and B vitamin combinations, more than 30,000 patients took supplements that lowered their homocysteine by roughly a quarter for years. Cardiovascular events did not decrease. (1,2,3,4,5,7)

B vitamins have indications the evidence supports. Cardiovascular event prevention — the use two decades of marketing implied — is not one the trials confirmed.

The trials moved the marker. They did not move the disease.

Article 17 examines antioxidant vitamins — a hypothesis that not only failed in randomized trials but produced evidence of harm, and what that pattern reveals about the difference between food that contains antioxidants and capsules that extract them.

Key Terms

Folate (vitamin B9): A B vitamin essential for DNA synthesis, cell division, and homocysteine metabolism. Central to neural tube defect prevention in pregnancy. Does not prevent cardiovascular events.

Homocysteine: An amino acid produced during methionine metabolism. Elevated levels correlate with cardiovascular disease in observational studies. Lowering homocysteine with B vitamins does not reduce cardiovascular events.

Marker hypothesis: The explanation that homocysteine rises in the presence of underlying disease processes (kidney impairment, inflammation, vascular disease itself) rather than causing them. Lowering the marker without addressing the underlying pathology does not improve outcomes.

MTHFR (methylenetetrahydrofolate reductase): An enzyme in folate metabolism. Common genetic variants (notably C677T) modestly raise homocysteine. Heavily marketed as a reason for B vitamin supplementation; trial evidence does not support supplementation specifically for MTHFR variants as cardiovascular prevention.

Remethylation: The metabolic pathway that converts homocysteine back to methionine, using folate and B12 as cofactors.

Surrogate endpoint: A measurable marker — such as homocysteine level — used as a proxy for clinical outcomes. The homocysteine story is the clearest demonstration in this series that improving a surrogate does not guarantee improving outcomes.

Transsulfuration: The metabolic pathway that converts homocysteine to cysteine, using B6 as a cofactor.

Vitamin B12 (cobalamin): Essential for neurological function and hematopoiesis. Deficiency causes neuropathy, anemia, and in severe cases irreversible spinal cord damage. Increasingly common in older adults and universal in unsupplemented strict vegans.

References

1. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease (HOPE-2). N Engl J Med. 2006;354(15):1567–1577.
2. Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction (NORVIT). N Engl J Med. 2006;354(15):1578–1588.
3. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death (VISP). JAMA. 2004;291(5):565–575.
4. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors. JAMA. 2010;303(24):2486–2494.
5. VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke (VITATOPS). Lancet Neurol. 2010;9(9):855–865.
6. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325(7374):1202.
7. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37,485 individuals. Arch Intern Med. 2010;170(18):1622–1631.
8. US Preventive Services Task Force. Folic acid supplementation for the prevention of neural tube defects: US Preventive Services Task Force recommendation statement. JAMA. 2017;317(2):183–189.

HeartBuddi • Your heart. Own it. • This article is educational and is not a substitute for individualized medical advice.